Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non …
Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The
therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of …
therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of …
Recent developments in radiotherapy
DE Citrin - New England journal of medicine, 2017 - Mass Medical Soc
Recent Developments in Radiotherapy | New England Journal of Medicine Skip to main content
The New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
The New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
V Narayan, JS Barber-Rotenberg, IY Jung, SF Lacey… - Nature medicine, 2022 - nature.com
Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly
in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the …
in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the …
Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials
PURPOSE Women have more adverse events (AEs) from chemotherapy than men, but few
studies have investigated sex differences in immune or targeted therapies. We examined …
studies have investigated sex differences in immune or targeted therapies. We examined …
Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study
Aim Chemotherapy side effects are often reported in clinical trials; however, there is little
evidence about their incidence in routine clinical care. The objective of this study was to …
evidence about their incidence in routine clinical care. The objective of this study was to …
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3
HI Scher, MJ Morris, WM Stadler, C Higano… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Evolving treatments, disease phenotypes, and biology, together with a changing
drug development environment, have created the need to revise castration-resistant prostate …
drug development environment, have created the need to revise castration-resistant prostate …
[PDF][PDF] Validity and reliability of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO …
Importance To integrate the patient perspective into adverse event reporting, the National
Cancer Institute developed a patient-reported outcomes version of the Common …
Cancer Institute developed a patient-reported outcomes version of the Common …
Integration of oncology and palliative care: a Lancet Oncology Commission
S Kaasa, JH Loge, M Aapro, T Albreht… - The lancet …, 2018 - thelancet.com
Full integration of oncology and palliative care relies on the specific knowledge and skills of
two modes of care: the tumour-directed approach, the main focus of which is on treating the …
two modes of care: the tumour-directed approach, the main focus of which is on treating the …
Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis
Objective To describe the development and validation of a novel patient reported outcome
measure for symptom burden from long covid, the symptom burden questionnaire for long …
measure for symptom burden from long covid, the symptom burden questionnaire for long …
Adverse effects of low-dose methotrexate: a randomized trial
DH Solomon, RJ Glynn, EW Karlson, F Lu… - Annals of internal …, 2020 - acpjournals.org
Background: Low-dose methotrexate (LD-MTX) is the most commonly used drug for
systemic rheumatic diseases worldwide and is the recommended first-line agent for …
systemic rheumatic diseases worldwide and is the recommended first-line agent for …